Floatz logo

Nktr-255

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Nektar TherapeuticsPhase 2/3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
89/ 100

Competitive context

107 Active assets in the Relapsed/Refractory Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB

View all 50 →

Same molecule, other indications

Nktr-255 is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
lung cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →